The Latest

Regen Med was honored to present alongside representatives of ESSKA and ESMA at ASTAOR’s International Sports Medicine Conference, held in Moscow November 21 and 22. Over 400 physicians and scientists from Europe, Russia and other countries were in attendance. The several highlights of the conference included a fascinating presentation by Oleg Atemiev, a cosmonaut who has logged more than 366 days in space, and has been awarded the prestigious Hero of the Russian Federation medal. It was a clear reminder that the science and clinical practice of sports medicine, at a high level, is relevant not only to Olympic and professional athletes, but to those brave men and women who venture into the cosmos. (As an interesting historical note, the co-President of ASTAOR and internationally respected orthopedic surgeon Alexei V. Korolev, is the grandson of the man considered the driving force behind the Soviet space program.)In his presentation, Regen Med’s CEO and co-founder Michael P. Tierney spoke to the close relationship between sports medicine and regenerative medicine – including the focus on “pre-“ and rehabilitation, team care, minimizing surgery and harnessing the body’s innate reparative, regenerative and immunomodulatory properties. He also addressed the increased importance for physicians, patients, regulators and industry of “real-world evidence”, both in and outside of the clinic. As was evident in virtually all of the talks given at the conference, the best evidence is often found on the ice, the football field, the ski slopes – or indeed, in outer space.For more information on building a clinical practice which is evidence-based, professionally fulfilling and financially successful see RMCE Networks and inCytes™.

SummaryRegen Med was a sponsor and exhibitor at the recent ISIAT meeting in Lisbon Portugal, whose main theme was the local treatment of joint diseases by intra-articular administration of therapeutic agents. The Symposium drew over 500 attendees from 53 countries who, over the three days of the meeting, debated intra-articular access, therapeutic targets & tools and future developments.3-5 October 2019, Lisbon, PortugalKey take-home messages:Clinical evidence for regenerative intra-articular therapies is in need of strengthening and Regen Med’s inCytes platform was viewed by many of the participants and sponsors as an optimal tool for the collection of prospective real-world evidence to support these therapies.‍ISIAT does significant work in the definition of guidelines for the treatment of important musculoskeletal pathologies and clinical evidence is key in allowing expert panels to define the positioning of different treatment modalities along the continuum of care.The topic of prevention rather than treatment of joint conditions was discussed in several sessions and this was viewed by many participants as an area where regenerative medicine can bring significant value. The demonstration of preventive benefits is a long-term undertaking requiring flexible and reliable data collection tools which guarantee as much as possible physician and patient compliance over time.Regen Med had the opportunity to hold meetings with all of the manufacturers sponsoring the meeting and to illustrate to them how the physician - and patient-friendly features of the inCytes Correlatable Observational Registries (COR’s) can improve data-entry compliance from these two key participant groups in longitudinal data collection projects, whether they be for regulatory purposes or have post-marketing objectives.Attending physicians visiting the Regen Med booth were able to learn first-hand how inCytes, and in particular the new feature-rich update which will be launched in early 2020, can reduce the direct burden on them in data collection and improve patient retention.Follow-up discussions with both commercial and physician ISIAT attendees on the use of inCytes in specific projects are now ongoing.There was also strong interest from attendees in Regen Med’s proposal to co-invest with clinical partners to establish, operate and expand networks of Regenerative Medicine Centers of Excellence. Project planning for such networks is now continuing with interested parties from France, Poland, Italy, Germany, Slovenia and Serbia.

AbstractHealthcare is about telling stories. Patients telling stories to doctors, doctors sharing stories with colleagues, and organizations building stories around their brands. The most effective stories are grounded in facts, and in today’s modern world, such evidence has never been easier to discover.inCytes™ is a clinical evidence application, yet it so much more. Through its engaging interfaces, user-specific experiences, and social collaboration, inCytes™ is a tool for building and sharing stories.DOWNLOAD WHITE PAPER

SummaryRegen Med was in attendance at the recent ICRS meeting in Vancouver, Canada, to connect with global scientists, clinicians and industry in the pursuit of improved cartilage repair, replacement and regeneration.Key takeaways included:Regen Med sat down with Profs. Lisa Fortier, Daniel Grande, and Dr. John Kennedy to form a Clinical/Scientific Advisory Board for its Regenerative Medicine Services of New York “RMSNY”. RMSNY will act as a managed services company, providing funding, support and guidance to affiliated Regenerative Medicine centers and its clinicians in the NY area. Immediate Board activities will include determining the high standards of excellence required amongst clinics and clinicians to participate in its clinical network. The first approved center, Tribeca Center for Regenerative Medicine, opens in Q1 2020.The ICRS patient registry distributed its first annual report since its inception and announcement in Sorrento, 2016. Despite the inherent and unavoidable challenges in typical registries, its membership seems to be growing in number and contributions. inCytes was introduced and is being currently vetted as a suitable platform for ICRS’ plans of expansion.Registries were a common topic of interest among the exhibiting sponsors. Most companies had prior experience with having run a registry in the past, and the more sizable companies had several concurrent registries ongoing. Challenges in compliance, motivation, incentives and validity of aggregated data seemed to be shared by all. We presented our COR product, powered through inCytes, as a solution to those typical problems. We are responding to several RFPs and hope to launch these CORS in early 2020.We are in discussions with several other key attendees for the formation of RMCE networks in Poland, Israel, Germany, Amsterdam, France and Italy, and were able to reconnect with many to further those discussions.Regen Med will next attend and speak at the Sports Medicine International Congress in Moscow on November 22-24th.

Ever-more powerful algorithms are “crawling” through the petabytes of insurance claims, PROM’s, pharmacy, genome and other healthcare databases in an attempt to drive more efficient therapies and medications and to help control spiraling medical costs. However, the results have lagged the promise. See here and here for two examples (from the American Medical Association, and Harvard Medical School).A major reason for disappointment with “big data” is the absence of data which are reliable (collected real-time), longitudinal (integrated across the patient’s entire treatment path) and clinically-relevant (represents the scientific and clinical criteria associated in the respected medical literature with better outcomes).Such useful data are notoriously difficult to obtain. By definition, they should be collected before, at and after the point of care by treating physicians or their assistants. However, those healthcare professionals are already overburdened by their clinical responsibilities, as well as other data-entry requirements increasingly demanded by government and insurers. Practicing physicians are often uncertain as to which clinical/scientific data should be collected. Pre-treatment and post-discharge outcomes data are, at best, episodic and poorly correlated with clinical data. Moreover, they are often not standardized and are difficult to obtain.inCytes™ was developed by leading product-independent clinicians and medical scientists. It is now being used to address the foregoing obstacles. It is an important tool, efficient and low-cost for any group – hospitals, ACO’s, payors, regulators, clinicians and researchers — seeking to develop evidence-based, superior, predictable and lower-cost outcomes over the long term for broad patient groups.